clinical trial · NCT03273023
PROMUS PREMIER™ China Post-Approval Study
Coronary Artery DiseasePromus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System
brief summary
To compile real-world clinical outcome data for the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System (Promus PREMIERTM Stent System) in routine clinical practice in China.
started
Jan 11, 2018
primary completion
Dec 28, 2020
completion
Oct 3, 2025
last updated
Mar 31, 2026
detailed description
Each site will be allowed to enroll up to a maximum of 300 subjects. The scheduled follow up will occur at 30 days, 6 months, 12 months and then annually through 5 years post stent implant, for all enrolled subjects. Follow-up will be conducted via telephone contact or clinic visit
official title
Post-Approval Study of the PROMUS PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System in China
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol